Geron | Working to change the course of blood cancers
Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives.
Geron Corporation - Geron Announces FDA Approval of …
2024年6月6日 · Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration. Geron aims to …
FDA approves imetelstat for low- to intermediate-1 risk …
On June 6, 2024, the Food and Drug Administration approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk...
Geron finally brings a drug to market as FDA clears Rytelo
5 天之前 · More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.
Geron Corporation - Investors & Media
2025年3月19日 · Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult …
生物制药公司Geron端粒酶抑制剂RYTELO™获FDA批准，用于治疗 …
2024年6月7日 · FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the …
Geron Corporation - Geron Announces European Commission …
2025年3月11日 · Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ …
Geron Announces European Commission Approval of RYTELO® …
2025年3月11日 · FOSTER CITY, Calif.-- (BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing …
FDA Approves Geron's First Commercial Drug, Competes With …
2024年6月7日 · On Thursday, the FDA approved Geron Corporation's (NASDAQ: GERN) Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) …
三十年磨一剑：调控生命时钟，全球首创端粒酶抑制剂上市 注：本 …
2024年9月18日 · 药融云数据显示：2024年6月6日，美国生物制药公司Geron Corporation（杰龙）宣布其开发的First-in-Class端粒酶抑制剂RYTELO（Imetelstat）获得FDA批准用于治疗低 …